Silence Therapeutics Raises $201M in Upsized ADS Offering

Event summary

Silence Therapeutics closed an upsized public offering of 14.9M ADSs at $13.50 per share, raising ~$201.3M before expenses.
Underwriters exercised their option to purchase an additional 1.9M ADSs.
The offering was led by Jefferies, Morgan Stanley, Cantor, and William Blair as joint book-running managers.
Proceeds will support the company's pipeline of siRNA therapies targeting rare and common diseases.

The big picture

Silence Therapeutics' successful upsized offering reflects strong investor confidence in the siRNA therapeutics sector, particularly for clinical-stage biotech companies with promising pipelines. The $201M raise positions Silence to advance its precision-engineered medicines, aligning with broader industry trends toward targeted gene-silencing treatments.

What we're watching

Pipeline Progression: How the capital infusion will accelerate Silence Therapeutics' clinical pipeline, particularly in areas of high unmet need.
Market Positioning: Whether the company can leverage this funding to strengthen its competitive edge in the siRNA therapeutics space.
Execution Risk: The pace at which Silence Therapeutics can translate its mRNAi GOLD™ platform into successful therapeutic outcomes.